Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma-Reference-Cited by-同舟云学术

Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma

Published:1998-03 Issue:3 Volume:100 Page:464-468
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Wen Yue-Jin,Ling Min,Lim Seah H.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.1998.00592.x/fullpdf

Reference10 articles.

1. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity;Campbell;Journal of Immunology,1990

2. Immunotherapy of established murine B cell lymphoma: combination of idiotype immunization and cyclophosphamide;Campbell;Journal of Immunology,1988

3. The host-tumor immune conflict: from immunosuppression to resistance and destruction;Chouaib;Immunology Today,1997

4. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors;Kwak;New England Journal of Medicine,1992

5. Transfer of myeloma idiotypic-specific immunity from an actively immunised marrow donor;Kwak;Lancet,1995

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The multi-faceted potential of CD38 antibody targeting in multiple myeloma;Cancer Immunology, Immunotherapy;2017-03-24

2. Construction and Characterization of Single-Chain Variable Fragment Antibody Library Derived from Germline Rearranged Immunoglobulin Variable Genes;PLoS ONE;2011-11-11

3. Targeting Human B-cell Malignancies through Ig Light Chain–Specific Cytotoxic T Lymphocytes;Clinical Cancer Research;2011-08-03

4. Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?;The Oncologist;2011-06-09

5. Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma;The Journal of Immunology;2009-01-20